David Badawi Sells 4,836 Shares of Sight Sciences (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 4,836 shares of the company’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $6.62, for a total value of $32,014.32. Following the sale, the chief technology officer owned 1,912,273 shares in the company, valued at approximately $12,659,247.26. This trade represents a 0.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

David Badawi also recently made the following trade(s):

• On Tuesday, January 6th, David Badawi sold 3,695 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total value of $27,638.60.
• On Monday, January 5th, David Badawi sold 3,051 shares of Sight Sciences stock. The stock was sold at an average price of $7.82, for a total value of $23,858.82.
• On Friday, January 2nd, David Badawi sold 2,914 shares of Sight Sciences stock. The shares were sold at an average price of $7.43, for a total transaction of $21,651.02.

Sight Sciences Stock Up 2.2%

Sight Sciences stock traded up $0.14 during trading on Wednesday, reaching $6.38. The stock had a trading volume of 326,019 shares, compared to its average volume of 315,994. Sight Sciences, Inc. has a 52-week low of $2.03 and a 52-week high of $9.24. The business has a 50 day moving average price of $7.81 and a 200 day moving average price of $5.32. The company has a quick ratio of 8.93, a current ratio of 9.60 and a debt-to-equity ratio of 0.62. The stock has a market cap of $337.31 million, a PE ratio of -7.09 and a beta of 2.42.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.10. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. The company had revenue of $19.91 million for the quarter, compared to the consensus estimate of $17.74 million. On average, analysts predict that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on SGHT. Citigroup raised their price target on Sight Sciences from $5.50 to $9.10 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Morgan Stanley increased their price objective on Sight Sciences from $6.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Sight Sciences in a research report on Monday, December 29th. Raymond James Financial set a $9.00 price target on Sight Sciences in a report on Monday, January 5th. Finally, Lake Street Capital increased their price target on shares of Sight Sciences from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, October 21st. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $8.30.

Institutional Trading of Sight Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in SGHT. Americana Partners LLC purchased a new position in shares of Sight Sciences in the 2nd quarter valued at approximately $3,568,000. Vanguard Group Inc. raised its position in Sight Sciences by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company’s stock worth $6,559,000 after buying an additional 102,609 shares during the last quarter. B Group Inc. lifted its position in Sight Sciences by 11.6% in the second quarter. B Group Inc. now owns 930,000 shares of the company’s stock valued at $3,841,000 after purchasing an additional 96,400 shares during the period. Palumbo Wealth Management LLC acquired a new position in Sight Sciences during the 2nd quarter worth approximately $328,000. Finally, Millennium Management LLC raised its stake in shares of Sight Sciences by 145.2% during the 3rd quarter. Millennium Management LLC now owns 133,846 shares of the company’s stock worth $460,000 after buying an additional 79,265 shares in the last quarter. 55.51% of the stock is owned by hedge funds and other institutional investors.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.